Izumi K, Shibata M, Togei K, Akagi A, Otsuka H, Jacobs J B, Ozono S, Miyata Y, Oyasu R
Gan. 1984 Sep;75(9):756-62.
12-O-Tetradecanoylphorbol-13-acetate (TPA), a potent promoter of mouse skin carcinogenesis, was tested for possible tumor-enhancing effects on urinary bladder carcinogenesis using the heterotopically transplanted bladder (HTB) model. Weekly administration of TPA at 1.0 microgram/week to N-methyl-N-nitrosourea-initiated HTBs did not increase tumor incidence, but instead, resulted in a significantly high incidence of nodulopapillary hyperplasia, an early neoplastic lesion, suggesting possible tumor enhancement by TPA. In addition, administration of a high dose of TPA with or without a carcinogen treatment led to the development of numerous finger-like epithelial projections on the luminal surface of the HTBs. Evidence indicates that epithelial projections are formed as a result of proliferation of intermediate cells. Whether these structures evolve into true neoplastic lesions is at present unknown.
12 - 十四酰佛波醇 - 13 - 乙酸酯（TPA）是一种强效的小鼠皮肤癌发生促进剂，使用异位移植膀胱（HTB）模型测试其对膀胱癌发生的潜在肿瘤增强作用。每周以1.0微克/周的剂量给经N - 甲基 - N - 亚硝基脲启动的HTB注射TPA，并未增加肿瘤发生率，反而导致结节状乳头增生（一种早期肿瘤病变）的发生率显著升高，提示TPA可能具有肿瘤增强作用。此外，无论是否进行致癌物处理，给予高剂量TPA都会导致HTB管腔表面出现大量指状上皮突起。有证据表明，上皮突起是中间细胞增殖的结果。目前尚不清楚这些结构是否会演变成真正的肿瘤病变。
